NCT06624085 2026-04-02A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaHoffmann-La RochePhase 1 Recruiting50 enrolled
NCT03223610 2026-04-01Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaNational Institutes of Health Clinical Center (CC)Phase 1/2 Recruiting155 enrolled